Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Ernst & Young: The Best Practice for Firms In The Current Climate




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Ernst & Young: The Best Practice for Firms In The Current Climate
Released on: January 18, 2010. © PharmaVentures Ltd
Visitors: You are watching a 30 seconds preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Paul Larsmon talks with Siegfried Bialojan, Head of Global Life Science Centre, Ernst & Young.

Filmed at BIO-Europe 2009, they discuss:

• trends identified over the last year
• the funding crisis balanced with creative deal-making
• how some small biotechs are finding it difficult to survive
• sustainable solutions to survival in the current market
• short-term vs. long-term strategies
• Siegfried's views on the future of healthcare business models
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Trends identified over the last year.
Paul Larsmon:
Hello and welcome to BIO-Europe 2009 here in the Austrian capital of Vienna. With me today is Seigfried Bialojan from Ernst & Young, welcome.
Seigfried Bialojan:
Thank you.
Paul Larsmon:
You've created a number of reports on the healthcare sector of the year, so what sort of trends have you identified here in Vienna?
Seigfried Bialojan:
Well we do this in pharma and biotech particularly also in the medical device area. I think if we talk about trends I think it's an overall theme that we have this convergence, it's very much realized both in the pharma side and the biotech side that it's a good thing to work together, right both in the need for innovation on the pharma side on the one hand and on the other hand of course the need for selling this kind of information and innovation from the biotech side in order to get funding also. So both of these things play together, and I think that's a pretty fruitful collaboration and we will see more of that, I guess.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Siegfried Bialojan
Head of Life Science Centre in Germany
Ernst & Young
Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. We aim to have a positive impact on businesses and markets, as well as on society as a whole.